Mathias M Hauri-Hohl

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Peritoneal Dialysis

Patients Undergoing

Allogeneic Hematopoietic Stem Cell Transplantation

Acute Lymphoblastic Leukemia

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Tim Bognàr, Moises Garcia-Rosa, Arief Lalmohamed, Tayfun Güngör, Mathias M Hauri-Hohl, Susan E Prockop, Layne M Oram, Sung-Yun Pai, Jordan Brooks, Rada M Savic, Christopher C Dvorak, Janel R Long-Boyle, Maja Krajinovic, Henrique Bittencourt, Anne-Charlotte Teyssier, Yves Theoret, Caridad Martinez, Antoine C G Egberts, Erin Morales, Mary A Slatter, Geoffrey D E Cuvelier, Robert Chiesa, Robert Wynn, Mary Coussons, Maria Pia Cicalese, Marc Ansari, Susan E Long, Christen L Ebens, Hannah Lust, Sonali Chaudhury, Christa Ellen Nath, Peter J Shaw, Steven John Keogh, M Y Eileen C van der Stoep, Robbert G M Bredius, Caroline A Lindemans, Jaap-Jan Boelens, Imke H Bartelink
Association of Busulfan Exposure and Outcomes after HCT for Patients with an Inborn Error of Immunity. Blood advances (2024)
Katharina M Schreib, Dominic S Bräm, Ulrike Barbara Zeilhofer, Daniel Müller, Tayfun Güngör, Stefanie D Krämer, Mathias M Hauri-Hohl
Population Pharmacokinetic Modeling for Twice-Daily Intravenous Busulfan in a Large Cohort of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation-A 10-Year Single-Center Experience. Pharmaceutics 16 (1) (2023)
Katharina M Schreib, Dominic S Bräm, Ulrike Barbara Zeilhofer, Daniel Müller, Tayfun Güngör, Stefanie D Krämer, Mathias M Hauri-Hohl
Population Pharmacokinetic Modeling for Twice-Daily Intravenous Busulfan in a Large Cohort of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation-A 10-Year Single-Center Experience. Pharmaceutics 16 (1) (2023)
Katharina M Schreib, Dominic S Bräm, Ulrike Barbara Zeilhofer, Daniel Müller, Tayfun Güngör, Stefanie D Krämer, Mathias M Hauri-Hohl
Population Pharmacokinetic Modeling for Twice-Daily Intravenous Busulfan in a Large Cohort of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation-A 10-Year Single-Center Experience. Pharmaceutics 16 (1) (2023)